CANY
BEAM icon

Caxton Associates (New York)’s Beam Therapeutics BEAM Stock Holding History

Caxton Associates (New York)’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,703
Closed -$509K – 464
2023
Q4 		$509K Buy
+18,703
New +$465K 0.03% 318

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Caxton Associates (New York)'s BEAM Position: Q1 2024 in Review

Caxton Associates (New York) sold out of Beam Therapeutics (BEAM) in Q1 2024, closing a stake of 18,703 shares — an estimated $509K sold.

Caxton Associates (New York) first reported a position in BEAM in Q4 2023 and held it in 1 quarter. The position peaked at $509K in Q4 2023. 221 funds tracked by Wall St. Rank hold BEAM as of Q1 2024.

  • Caxton Associates (New York) reported no remaining Beam Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Caxton Associates (New York) sold 18,703 Beam Therapeutics shares in Q1 2024, an estimated $509K.
  • Caxton Associates (New York) first reported a position in Beam Therapeutics in Q4 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Beam Therapeutics position peaked at $509K in Q4 2023.
  • 221 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2024.

Based on Caxton Associates (New York)'s 13F filing for Q1 2024, filed 15 May 2024.